Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP raised its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 669,600 shares of the biopharmaceutical company's stock after buying an additional 26,054 shares during the quarter. Westfield Capital Management Co. LP owned about 0.88% of Xenon Pharmaceuticals worth $26,362,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Driehaus Capital Management LLC increased its holdings in shares of Xenon Pharmaceuticals by 2.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company's stock worth $172,315,000 after buying an additional 97,732 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in Xenon Pharmaceuticals by 18.7% during the second quarter. Affinity Asset Advisors LLC now owns 994,227 shares of the biopharmaceutical company's stock worth $38,765,000 after acquiring an additional 156,840 shares during the last quarter. TimesSquare Capital Management LLC increased its stake in Xenon Pharmaceuticals by 3.2% during the third quarter. TimesSquare Capital Management LLC now owns 778,293 shares of the biopharmaceutical company's stock worth $30,641,000 after acquiring an additional 23,800 shares during the last quarter. Samlyn Capital LLC raised its position in Xenon Pharmaceuticals by 61.5% during the second quarter. Samlyn Capital LLC now owns 639,685 shares of the biopharmaceutical company's stock valued at $24,941,000 after purchasing an additional 243,489 shares during the period. Finally, Fiera Capital Corp lifted its stake in shares of Xenon Pharmaceuticals by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 582,879 shares of the biopharmaceutical company's stock valued at $22,726,000 after purchasing an additional 6,337 shares during the last quarter. Institutional investors own 95.45% of the company's stock.

Xenon Pharmaceuticals Trading Up 1.3 %

Shares of XENE traded up $0.53 during midday trading on Monday, reaching $41.68. 483,983 shares of the stock were exchanged, compared to its average volume of 389,485. The company's 50 day moving average is $41.23 and its two-hundred day moving average is $40.19. The company has a market capitalization of $3.18 billion, a P/E ratio of -14.59 and a beta of 1.25. Xenon Pharmaceuticals Inc. has a 52 week low of $29.00 and a 52 week high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same quarter in the prior year, the business posted ($0.73) earnings per share. On average, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gary Patou sold 4,891 shares of the business's stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the transaction, the director now directly owns 23,573 shares in the company, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 5.52% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on XENE shares. HC Wainwright restated a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Needham & Company LLC reaffirmed a "buy" rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. Raymond James reissued an "outperform" rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 3rd. Eleven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Xenon Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $57.45.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.